TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03538756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkasins
Description: Walkasins® consist of two parts for each leg: the Haptic Module (leg unit) and the Receptor Sole (foot pad). The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkasins
Description: Walkasins® consist of two parts for each leg: the Haptic Module (leg unit) and the Receptor Sole (foot pad). The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkasins
Description: Walkasins® consist of two parts for each leg: the Haptic Module (leg unit) and the Receptor Sole (foot pad). The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
Study: NCT03995069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D
Description: Practice generating grip force to the target shown on the computer screen in 3 dimensions.
Study: NCT02603081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005
Description: Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005
Description: Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPI-1005
Description: Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.
Study: NCT01485042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib and TH-302
Description: Pazopanib 800 mg daily TH-302 IV on Days 1, 8, 15 at MTD Subjects will receive this regimen until disease progression.
Study: NCT03757000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (\>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
Study: NCT02446301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bain®
Description: Nalbuphine HCl 20mg, IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDE
Description: Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection
Study: NCT03816774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG split-dose and simethicone
Description: Patients in active comparator arm are instructed to take 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
Study: NCT01826864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy
Description: Undergo sentinel lymph node biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sentinel lymph node biopsy
Description: Undergo sentinel lymph node biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline
Description: Given SC
Study: NCT03511833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: IV morphine -0.1 mg/kg: Morphine vial contains 10 mg/10 ml = 1mg/ml ----\> 0.1 ml/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IN ketamine: 1 mg/kg: Ketamine vial contains 100 mg/2 ml = 50mg/ml ---\> 0.02ml/kg
Study: NCT01105611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg orally twice daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir/Ritonavir
Description: Atazanavir 300mg orally once daily boosted with Ritonavir orally 100mg once daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
Study: NCT01814969

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionated Radiochemotherapy
Description: 28 x 1.5Gy 2 times a day; gap between the fractions min. 6-8h - duration of treatment 2.5 weeks + simultaneous bolus 5-Fluorouracil (the each cycle consisted of 5-fluorouracil 325 mg/m2 per day) on 1-3 and 16-18 (last 3 days of radiotherapy).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hyperfractionated Radiotherapy
Description: 28 x 1.5Gy 2 times a day; gap between the factions min. 6-8h - duration of treatment 2.5 weeks
Study: NCT00737555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHR-2797
Description: Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
Study: NCT04636970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home training program
Description: Subjects randomized to the IG will participate at home training program that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after.
Study: NCT03830593

Intervention type: PROCEDURE
Intervention: Laparoscopic Adrenalectomy
Description: minimally invasive lateral transperitoneal adrenalectomy
Study: NCT03995069

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1D
Description: Practice generating grip force to the target shown on the computer screen in 1 dimension.
Study: NCT04877392

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lavender essential oil
Description: Use of inhaled lavender essential oil
Study: NCT03393442

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain MRI scan
Description: Diagnostic brain MRI scan with the purpose to detect signal changes due to brain deposits of Gd.
Study: NCT01112579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic PrimeADVANCED Neurostimulator
Description: Heart failure therapy

Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic PrimeADVANCED Neurostimulator
Description: Medical management
Study: NCT06094725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant 300 mg (3 X 100 mg softgel capsules) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant 300 mg (3 X 100 mg softgel capsules) for oral administration
Study: NCT00680602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavior Therapy
Description: Structured protocol described by Cordioli et al., 2003
Study: NCT03144713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
Study: NCT03393442

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRI scan
Description: Diagnostic brain MRI scan with the purpose to detect signal changes due to brain deposits of Gd.
Study: NCT05937113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RABIVAX-S
Description: 1 ml dose vaccine containing ≥ 2.5 IU of purified rabies antigen (Pitman-Moore rabies virus strain 3218; acclimatized and cultured on vero cells, inactivated with β propiolactone).~Pre-exposure prophylaxis regimens for two groups~* Intramuscular 1ml on days D0, D7 and D21+7~* Intradermal injection 0.1 ml on days D0, D7 and D21+7 Blood samples were collected on days D0, D7 and D21 - 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RABIVAX-S
Description: 1 ml dose vaccine containing ≥ 2.5 IU of purified rabies antigen (Pitman-Moore rabies virus strain 3218; acclimatized and cultured on vero cells, inactivated with β propiolactone).~Pre-exposure prophylaxis regimens for two groups~* Intramuscular 1ml on days D0, D7 and D21+7~* Intradermal injection 0.1 ml on days D0, D7 and D21+7 Blood samples were collected on days D0, D7 and D21 - 28
Study: NCT01987284

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SER100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER100

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04245878

Intervention type: OTHER
Intervention: gastric ultrasound
Description: gastric ultrasound for measurement of the antral area
Study: NCT03900702

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaze-driven training games
Description: Training games are played on a PC with attached eye-tracker. Games include embedded training principles to improve attentional control including resistance to distraction and inhibitory control.
Study: NCT03677713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No nasal packing.
Description: No nasal packing at the end of the surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Packing
Description: Patients will have nasal packing at the end of the surgery
Study: NCT00962728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Threshold Device (Res-Q-Gard ITD)
Description: Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Inspiratory Threshold Device
Description: Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
Study: NCT04062266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV
Study: NCT00680602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI (fluoxetine, sertraline, paroxetine, citalopram)
Description: Fluoxetine (80mg/day or maximum tolerated dosage) Sertraline (200mg/day or maximum tolerated dosage) Paroxetine (60 mg/day or maximum tolerated dosage) Citalopram (60 mg/day or maximum tolerated dosage)
Study: NCT01357070

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brocco-sprout homogenate
Description: Participants will be asked to orally consume on three consecutive days a brocco-sprout homogenate (70g dry weight).

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Alfalfa sprout homogenate
Description: Participants will be asked to orally consume on three consecutive days an alfalfa sprout homogenate.
Study: NCT01910584

Intervention type: PROCEDURE
Intervention: Novasure endometrial ablation
Description: Novasure endometrial ablation is the second generation endometrial ablation treatment aimed to cure the dysfunctional uterine bleeding(DUB),including menorrhagia.
Study: NCT01034436

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fatty acid quality and overweight
Description: Duration 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fatty acid quality and overweight
Description: Duration 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fatty acid quality and overweight
Description: Duration 12 weeks
Study: NCT03916549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
Study: NCT04062266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT00248365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Theralux extracorporeal photochemotherapy
Study: NCT01987284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02863679

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tetracaine hydrochloride gel
Description: Tetracaine hydrochloride gel contains 1% tetracaine hydrochloride, and a fair dose of fungicide, lubricants, remove foam agent, as the long-term local anesthetics.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine hydrochloride gel
Description: Tetracaine hydrochloride gel contains 1% tetracaine hydrochloride, and a fair dose of fungicide, lubricants, remove foam agent, as the long-term local anesthetics.
Study: NCT00838877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radioligand [18F]AZD4694
Description: single dose of iv. admin. 1-2 times per subject

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radioligand [11C]AZD2184
Description: single dose of iv admin. 1 time per subject
Study: NCT01992107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIVc
Description: Novartis Investigational Quadrivalent Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV1c
Description: Licensed Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV2c
Description: Novartis Investigational Vaccine
Study: NCT01604213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin plus vildagliptin
Description: Oral Metformin 850mg and vildagliptin 50mg, qd initially, up-titrated to BID if clinically necessary

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin only
Description: Oral Metformin 850mg QD, up-titrated to 850mg TID is clinically indicated
Study: NCT00804609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DepoDur following epidural lidocaine
Description: All participant underwent cesarean delivery. An epidural top-up anesthetic consisting of 2% lidocaine with epinephrine 1:200,000 and sodium bicarbonate (1 meq per 10 mL lidocaine) was given. The lidocaine solution was administered in 5 mL increments every 2.5 minutes until a T6 sensory level to touch was attained. Patients also received a 100 mcg dose of fentanyl epidurally after the lidocaine solution had been administered.~Provided delivery had occurred at least 60 minutes after the initial lidocaine administration, patients received EREM 8 mg (DepoDur™) administered through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DepoDur following spinal anesthetic
Description: Participants underwent an elective cesarean delivery with a combined spinal/epidural. All patients received 12 mg hyperbaric bupivacaine with 20 mcg fentanyl administered intrathecally. No local anesthetic was administered through the catheter. The combined spinal-epidural was performed at the L2/L3 or L3/L4 interspace and the intrathecal dose was injected over 5-10 s. A multiple orifice epidural catheter was threaded 5 cm into the epidural space.~Provided delivery had occurred 60 minutes after the intrathecal dose patients received EREM 8 mg (DepoDur™) through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug.
Study: NCT00817362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504
Description: IPI-504 IV infusion 300 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was \<4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.
Study: NCT02434133

Intervention type: PROCEDURE
Intervention: Blood Draw/Data Collection
Description: Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.

Intervention type: PROCEDURE
Intervention: Blood Draw/Data Collection
Description: Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.

Intervention type: PROCEDURE
Intervention: Blood Draw/Data Collection
Description: Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.

Intervention type: PROCEDURE
Intervention: Blood Draw/Data Collection
Description: Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.
Study: NCT02308540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIILPCV10
Description: 10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) at a dosage of 2 µg for each serotype polysaccharide, except 4 µg for 6B serotype, conjugated to a carrier protein (CRM197), with adjuvant (aluminum phosphate \[alum\]) and preservative (thiomersal).
Study: NCT03333850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual feedback of physical activity
Description: A monitor (tablet) will display the level of physical activity during hospitalisation. The monitor will be placed at the bedside (table).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No feedback of physical activity
Description: There will be no visual feedback of the physical activity (no monitor placed at the bedside (table)).
Study: NCT02308540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIILPCV10
Description: 10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) at a dosage of 2 µg for each serotype polysaccharide, except 4 µg for 6B serotype, conjugated to a carrier protein (CRM197), with adjuvant (aluminum phosphate \[alum\]) and preservative (thiomersal).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIILPCV10
Description: 10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) at a dosage of 2 µg for each serotype polysaccharide, except 4 µg for 6B serotype, conjugated to a carrier protein (CRM197), with adjuvant (aluminum phosphate \[alum\]) and preservative (thiomersal).
Study: NCT03333850

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of physical activity
Description: A pair of accelerometers placed on the chest and on the thigh will measure the physical activity level during hospitalisation. The measurement is made continuously and stored on a secure web-server.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of physical activity
Description: A pair of accelerometers placed on the chest and on the thigh will measure the physical activity level during hospitalisation. The measurement is made continuously and stored on a secure web-server.
Study: NCT02229006

Intervention type: RADIATION
Intervention: 18F-NaF PET-CT
Study: NCT02308540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIILPCV10
Description: 10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) at a dosage of 2 µg for each serotype polysaccharide, except 4 µg for 6B serotype, conjugated to a carrier protein (CRM197), with adjuvant (aluminum phosphate \[alum\]) and preservative (thiomersal).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax 23
Description: 23-valent Pneumococcal Polysaccharide Vaccine (Pneumovax 23; MSD Pharmaceuticals) for the adult cohort.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: 13-valent Pneumococcal Conjugate Vaccine (Prevenar 13; Pfizer-Wyeth) for the toddler and infant cohorts

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: 13-valent Pneumococcal Conjugate Vaccine (Prevenar 13; Pfizer-Wyeth) for the toddler and infant cohorts

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: 13-valent Pneumococcal Conjugate Vaccine (Prevenar 13; Pfizer-Wyeth) for the toddler and infant cohorts
Study: NCT03439761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT-112 Injection
Description: PT-112 Injection 28 days constitute a period. The drug is intravenously dripped for 60 minutes at the 1st, 8th and 15th day of each period.
Study: NCT01222520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan and amlodipine
Description: Telmisartan 80 mg and amlodipine 5 mg once a daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: 80 mg once a daily